Fenwick & West represented BioPharmX Corporation (NYSE: BPMX), a specialty pharmaceutical company focusing on dermatology and women's health, in its underwritten public offering of 3,600,000 shares of its common stock and warrants to purchase 1,800,000 shares of common stock for gross proceeds of approximately $4.3 million. The offering was made pursuant to an effective shelf registration statement previously filed with the SEC. As part of the offering, BioPharmX granted the underwriters an option for a period of 45 days to purchase up to an additional 324,000 shares of common stock and/or warrants to purchase up to an additional 162,000 shares of common stock at the public offering price. The underwriters partially exercised the option to purchase additional warrants to purchase 152,000 shares of common stock.
Maxim Group LLC acted as lead book-running manager and CRT Capital Group LLC acted as co-book-running manager for the offering. Rodman & Renshaw, a unit of H.C. Wainwright & Co., LLC, acted as co-manager for the offering.
The Fenwick transaction team included corporate partner Robert Freedman and associates Niki Fang, Philip Henry and David He.